WHO ICTRP trial
Phase 3b/4 Study of Aducanumab in Alzheimer's Disease
JPRN-jRCT2021220027 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2021220027 |
|---|---|
| Public title | Phase 3b/4 Study of Aducanumab in Alzheimer's Disease |
| Scientific title | A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer's Disease |
| Primary sponsor | Toda Yasuo |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | France;Japan;Italy;Japan;Spain;Japan;Germany;Japan;Portugal;Japan;Belgium;Japan;Finland;Japan;Poland;Japan;Switzerland;Japan;Sweden;Japan;South… |
| Conditions | Alzheimer's Disease |
| Interventions | Research Name : BIIB037 Generic Name : Aducanumab-avwa Trade Names : Aduhelm participants will receive either aducanumab 10 mg/kg or placebo IV every 4 weeks. |
| Registration date | Oct 25, 2022 |
| Target size | 1512 |
| Secondary IDs | NCT05310071 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: